Hemodynamic stress response to tracheal intubation during general anesthesia
Conditions
Interventions
Oliceridine group:Intravenous Ciprofol 0.7 mg/kg followed by Oliceridine administered using the modified Dixon up-and-down method. Initial dose 0.005 mg/kg, step size 0.005 mg/kg. Dose adjusted accord
Taijilidine group:Intravenous Ciprofol 0.7 mg/kg followed by Taijilidine using modified Dixon sequential allocation. Initial dose 0.005 mg/kg, step size 0.005 mg/kg.
Anruikefen group:Intravenous Ciprofol 0.7 mg/kg followed by Anruikefen using modified Dixon up-and-down method. Initial dose 1 µg/kg, step size 0.5 µg/kg.
Sponsors
The Affiliated Hospital of North China University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Age 18–65 years, either sex; 2.Body mass index (BMI) 15–30 kg/m^²; 3.ASA physical status I–III; 4.Patients scheduled for elective surgery under general anesthesia with tracheal intubation; 5.Mallampati class I–II, mouth opening =3 cm, normal neck mobility; 6.Cardiac function class I; 7.Written informed consent obtained.
Exclusion criteria
Exclusion criteria: 1.High risk of aspiration or anticipated difficult airway; 2.Severe hypertension (SBP =180 mmHg or DBP =110 mmHg); 3.Chronic opioid use; 4.BMI >30 kg/m^²; 5.Known allergy to study medications; 6.Adrenal insufficiency; 7.Unsuitable for tracheal intubation; 8.Refusal to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Median effective dose (ED50) for suppression of intubation response;Hemodynamic parameters (SBP, DBP, MAP, HR); | — |
Countries
China
Contacts
Public ContactLiutiejun
The Affiliated Hospital of North China University of Science and Technology
Outcome results
None listed